Department of Medical Oncology, Istanbul University Institute of Oncology, Medical Oncology, Çapa, Fatih, 34093, Istanbul, Turkey.
Department of Surgery, Istanbul University, Faculty of Medicine, Istanbul, Turkey.
J Cancer Res Clin Oncol. 2023 Nov;149(16):14833-14841. doi: 10.1007/s00432-023-05276-y. Epub 2023 Aug 18.
We evaluated the outcomes, and risk factors for recurrence in patients with early stage node-negative breast cancer in this study.
Retrospective data analysis was done on patient treatment records from 1988 to 2018. The patient's demographic, clinical, pathological, and therapeutic characteristics were noted. To evaluate survival analysis and predictors of recurrence, we employed Kaplan-Meier analysis with the log-rank test.
A total of 357 patients in all were enrolled in the research. At the time of diagnosis, the median age was 50 (with a range of 18-81). A total of 85.5% of patients had undergone a lumpectomy, while 14.5% had a mastectomy. 78.7% of patients had sentinel lymph node biopsy, and 21.3% had axillary lymph node dissection. In addition, the patients received adjuvant radiotherapy (88.7%), adjuvant endocrine therapy (82.1%), and adjuvant chemotherapy (48.5%). Recurrence of the tumor occurred in 31 (8.7%) patients (local recurrence 45.2% and metastatic disease 54.8%). Ten- and twenty-year recurrence-free survival rates were 92% and 77%. 19 (5.3%) patients had also developed contralateral breast cancer. Ten-year survival rates were 91.6%, and 20-year survival rates were 76.6%, respectively. Aged over 65 years (p = 0.004), necrosis (p = 0.002), mitosis (p = 0.003), and nuclear pleomorphism (p = 0.049) were found as statistically significant factors for recurrence in univariate analysis. In the ROC analysis, the largest size of the tumor (over 1.45 cm, p = 0.07) remained outside the statistical significance limit in terms of recurrence.
Thirty-year outcomes in individuals with early stage, node-negative breast cancer were shown in this study. We found that the recurrence ratios between 10 and 20 years were more frequent than the first 10 years during the follow-up. Despite the small number of patients who experienced a recurrence, we demonstrated that, in univariate analysis, being older than 65 and having some pathological characteristics (nuclear pleomorphism, mitosis, and necrosis) were statistically significant factors for disease recurrence.
本研究评估了早期淋巴结阴性乳腺癌患者的结局和复发风险因素。
对 1988 年至 2018 年患者的治疗记录进行回顾性数据分析。记录患者的人口统计学、临床、病理和治疗特征。为了评估生存分析和复发的预测因素,我们采用 Kaplan-Meier 分析和对数秩检验。
共纳入 357 例患者。诊断时中位年龄为 50 岁(范围为 18-81 岁)。85.5%的患者行乳房切除术,14.5%行乳房切除术。78.7%的患者行前哨淋巴结活检,21.3%的患者行腋窝淋巴结清扫术。此外,患者接受辅助放疗(88.7%)、辅助内分泌治疗(82.1%)和辅助化疗(48.5%)。31 例(8.7%)患者发生肿瘤复发(局部复发 45.2%,远处转移 54.8%)。10 年和 20 年无复发生存率分别为 92%和 77%。19 例(5.3%)患者还发生了对侧乳腺癌。10 年总生存率为 91.6%,20 年总生存率为 76.6%。年龄大于 65 岁(p=0.004)、坏死(p=0.002)、有丝分裂(p=0.003)和核多形性(p=0.049)在单因素分析中被认为是复发的统计学显著因素。在 ROC 分析中,肿瘤最大直径(超过 1.45cm,p=0.07)在随访期间仍未达到统计学显著水平。
本研究显示了早期淋巴结阴性乳腺癌患者 30 年的结果。我们发现,在随访期间,10 年至 20 年的复发率高于前 10 年。尽管复发患者人数较少,但我们的单因素分析表明,年龄大于 65 岁以及具有某些病理特征(核多形性、有丝分裂和坏死)是疾病复发的统计学显著因素。